Dr. Wolf-Achim Hassenpflug
Claim this profileUniversitaetsklinikum Hamburg-Eppendorf
Studies Thrombotic Thrombocytopenic Purpura
Studies TTP
3 reported clinical trials
5 drugs studied
Area of expertise
1Thrombotic Thrombocytopenic Purpura
ADAMTS13 positive
ADAMTS-13 positive
ADAMTS-13 negative
2TTP
ADAMTS13 positive
ADAMTS-13 positive
ADAMTS-13 negative
Clinical Trials Wolf-Achim Hassenpflug is currently running
TAK-755
for Purpura
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur. People who have TTP may bleed underneath the skin forming purple bruises, or purpura. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them, leading to fewer red blood cells than in normal. TTP is caused by a lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in controlling clotting of the blood. The ADAMTS13 enzyme breaks up another blood protein called von Willebrand factor that forms blood clots by clumping together with platelets. Some people are born with this condition, while others develop the condition during their life. Many people who are born with TTP experience frequent flare-ups that need to be treated right away. TAK-755 is a medicine that replaces ADAMTS13 and may prevent or control TTP flare-ups, called acute TTP events. The main aim of the study is to check for side effects of long-term treatment with TAK-755. Treatment will be given in 2 ways: 1. TAK-755 treatment given either every week or every other week to prevent acute TTP events from happening (the "prophylactic" cohort). 2. TAK-755 treatment given to control an acute TTP event when it happens (the "on-demand" cohort). Participants in the prophylactic cohort will receive treatment in the clinic or at home for up to approximately 3 years. They will visit the clinic at least every 12 weeks. Participants in the on-demand cohort will receive daily treatment for the acute TTP event until the flare-up has gotten better. They will have a follow-up visit at the clinic 4 weeks later.
Recruiting2 awards Phase 310 criteria
rVWF +/− ADVATE
for Von Willebrand Disease
The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor \[rVWF\]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (\<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with vonicog alfa for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's usual clinical practice. During the study, participants will be followed up at clinics or over telephone calls.
Recruiting2 awards Phase 3
More about Wolf-Achim Hassenpflug
Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Wolf-Achim Hassenpflug has experience with
- Antihemophilic Factor (Recombinant)
- Von Willebrand Factor (Recombinant)
- BAX 930
- Standard Of Care
- TAK-755
Breakdown of trials Wolf-Achim Hassenpflug has run
Thrombotic Thrombocytopenic Purpura
Von Willebrand Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Wolf-Achim Hassenpflug specialize in?
Wolf-Achim Hassenpflug focuses on Thrombotic Thrombocytopenic Purpura and TTP. In particular, much of their work with Thrombotic Thrombocytopenic Purpura has involved ADAMTS13 positive patients, or patients who are ADAMTS-13 positive.
Is Wolf-Achim Hassenpflug currently recruiting for clinical trials?
Yes, Wolf-Achim Hassenpflug is currently recruiting for 2 clinical trials in the USA. If you're interested in participating, you should apply.
Are there any treatments that Wolf-Achim Hassenpflug has studied deeply?
Yes, Wolf-Achim Hassenpflug has studied treatments such as Antihemophilic Factor (Recombinant), von Willebrand factor (Recombinant), BAX 930.
What is the best way to schedule an appointment with Wolf-Achim Hassenpflug?
Apply for one of the trials that Wolf-Achim Hassenpflug is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.